– FRANCE, Marseille – Innate Pharma SA (EPA: IPH / Nasdaq: IPHA) announced the proposition to move its corporate governance structure from an executive board/supervisory board to one with a CEO/board of directors.
The company has nominated the following individuals as members of the board of Directors to be appointed by shareholders at the next 2025 AGM.
- Irina Staatz Granzer (Current Chair of the Supervisory Board to become Board Chair);
- Jonathan Dickinson (current Chairman of the Executive Board to become CEO)
- Véronique Chabernaud;
- Pascale Boissel;
- Bpifrance Participations, represented by Olivier Martinez;
- Sally Bennett;
- Christian Itin (new)
- Marty J. Duvall (new).
About Marty J. Duvall
Marty J. Duvall is an accomplished and passionate biotech executive based in the U.S., with over 35 years of experience building companies in the pharma and biotechnology industry, focused on specialty therapeutics. He’s a Global Builder of Companies and Brands in Oncology.. His big pharma experience includes global oncology leadership positions at Aventis and Merck. His biotech experience includes C-level contributions to company builds leading to value-creating transactions at MGI Pharma, Abraxis Bioscience, and ARIAD, where he worked to build a footprint across the US, Europe, and Asia.
His CEO experience includes both public companies (Tocagen and Oncopeptides) as well as private companies (Angiex) and includes a successful IPO and follow-on financings under his leadership.
With an oncology focus over the last three decades, Marty J. Duvall has helped launch and drive many successful therapeutics that have benefited patients with a wide range of cancers, including breast, lung, prostate, gastric, head and neck, brain, melanoma, myelodysplastic syndrome, leukemia, and multiple myeloma.
About Dr. Christian Itin
Christian Itin is a very seasoned biotechnology company leader with more than 25 years of industry experience. He serves as CEO of Autolus Therapeutics (Nasdaq: AUTL). He built Autolus into a fully integrated biopharmaceutical company, commercializing its first CAR-TT cell therapy product, Aucatzyl,® approved by the US FDA in November 2024.
Previously, Christian was President and CEO of Micromet Inc., a formerly Nasdaq-listed biopharmaceutical company acquired in March 2012 by Amgen, Inc. for USD 1.2 billion. Micromet developed the first T-cell engaging antibody Blincyto®, now standard of care for the treatment of B-cell acute leukaemia.
From 2016 to 20,19, Christian was on the board of Kuros Biosciences (SIX: KURN), serving as chairman from 2016 to 2018. Before Kuros, he served as executive chairman of Cytos Biotechnology Ltd from 2012 to 2016 until its merger with Kuros Biosurgery, forming Kuros Biosciences. Kuros developed and is commercializing MagnetOS™, a synthetic bone graft replacing boallo- or-or xenografts. Christian also served as non-executive director on the board of Kymab, Ltd, a privately held UK company, from 2012 until its acquisition by Sanofi in 2021 for a USD 1.1 billion upfront payment plus additional milestones.
He has a diploma in biology and holds a PhD in cell biology summa cum laude from the University of Basel, Switzerland and performed post-doctoral research at the Biocenter of Basel University and Stanford University School of Medicine, CA, USA.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform, and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research, and development for the benefit of patients.
Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
For more: www.innate-pharma.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.